Pharmacological approaches to the prevention of type 2 diabetes mellitus

Frontiers in Endocrinology

Endocrinology

Dinesh Edem¹  Faustina Alejandra Lozada Orquera²  Priyanka Majety²  Osama Hamdy³ 

[1] Division of Endocrinology, Diabetes and Metabolism, University of Arkansas Medical Center, Little Rock, AR, United States;Division of Endocrinology, Diabetes and Metabolism, Virginia Commonwealth University Health System, Richmond, VA, United States;Joslin Diabetes Center, Harvard Medical School, Boston, MA, United States;

关键词: type 2 diabetes mellitus;    prevention;    metformin;    prediabetes;    remission;    pharmacotherapy;   

DOI  :  10.3389/fendo.2023.1118848

 received in 2022-12-08, accepted in 2023-02-13,  发布年份 2023

来源: Frontiers

【 摘 要 】

About 1 in 10 adults worldwide are estimated to have diabetes mellitus. They are at risk of developing life-threatening complications resulting in reduced quality of life, increased mortality and higher healthcare costs. The ability to prevent or delay type 2 diabetes mellitus (T2DM) by modifying some of its risk factors has been hypothesized for decades. The long and often gradual time-course of increasing dysglycemia prior to diabetes diagnosis suggests that interventions during that period could be effective in preventing T2DM. In addition to lifestyle modifications, certain drugs prevent or slow development of hyperglycemia. Recently, drugs used for obesity management were shown to prevent T2DM. In this review, we discuss various pharmacotherapeutic options for preventing T2DM.

【 授权许可】

Unknown   
Copyright © 2023 Majety, Lozada Orquera, Edem and Hamdy